- Home
- NTRB vs RLYB Comparison
NTRB vs RLYB Comparison
Compare NTRB & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTRB
- RLYB
- Stock Information
- Founded
- NTRB 2016
- RLYB 2018
- Country
- NTRB United States
- RLYB United States
- Employees
- NTRB N/A
- RLYB N/A
- Industry
- NTRB Industrial Specialties
- RLYB Biotechnology: Pharmaceutical Preparations
- Sector
- NTRB Health Care
- RLYB Health Care
- Exchange
- NTRB Nasdaq
- RLYB Nasdaq
- Market Cap
- NTRB 93.2M
- RLYB 24.1M
- IPO Year
- NTRB N/A
- RLYB 2021
- Fundamental
- Price
- NTRB $6.91
- RLYB $0.70
- Analyst Decision
- NTRB Buy
- RLYB Hold
- Analyst Count
- NTRB 1
- RLYB 2
- Target Price
- NTRB $13.00
- RLYB N/A
- AVG Volume (30 Days)
- NTRB 48.5K
- RLYB 256.1K
- Earning Date
- NTRB 12-03-2025
- RLYB 11-07-2025
- Dividend Yield
- NTRB N/A
- RLYB N/A
- EPS Growth
- NTRB N/A
- RLYB N/A
- EPS
- NTRB N/A
- RLYB N/A
- Revenue
- NTRB $2,578,059.00
- RLYB $761,000.00
- Revenue This Year
- NTRB $560.75
- RLYB N/A
- Revenue Next Year
- NTRB $588.39
- RLYB N/A
- P/E Ratio
- NTRB N/A
- RLYB N/A
- Revenue Growth
- NTRB 42.92
- RLYB 154.51
- 52 Week Low
- NTRB $2.98
- RLYB $0.22
- 52 Week High
- NTRB $9.42
- RLYB $1.24
- Technical
- Relative Strength Index (RSI)
- NTRB 44.60
- RLYB 70.43
- Support Level
- NTRB $7.00
- RLYB $0.54
- Resistance Level
- NTRB $8.25
- RLYB $0.68
- Average True Range (ATR)
- NTRB 0.50
- RLYB 0.05
- MACD
- NTRB -0.07
- RLYB 0.01
- Stochastic Oscillator
- NTRB 6.94
- RLYB 90.09
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.